SGLT2 inhibitors — including empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin — have reshaped the management of type 2 diabetes. Originally developed as glucose-lowering agents, they are now recognized for their cardiorenal protective effects, with guideline recommendations extending well beyond glycemic control. This article reviews the mechanism, evidence, clinical applications, and safety considerations for this transformative drug class.
- What Are SGLT2 Inhibitors and How Do They Work?
- Cardiovascular and Renal Benefits: The Evidence Base
- Approved SGLT2 Inhibitors: Comparison and Key Differences
- Glycemic Efficacy and Place in Therapy
- Safety Profile, Side Effects, and Contraindications
- Patient Selection and Practical Prescribing
- Common Myths and Misconceptions About SGLT2 Inhibitors
- Frequently Asked Questions
What Are SGLT2 Inhibitors and How Do They Work?
SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors), also called gliflozins, are a class of oral glucose-lowering medications that act on the proximal renal tubule to reduce glucose reabsorption. By inhibiting the SGLT2 protein — which is responsible for approximately 90% of renal glucose reabsorption — these drugs induce glucosuria, thereby lowering plasma glucose concentrations independently of insulin secretion or action.
This insulin-independent mechanism explains several unique properties of the class: a low intrinsic risk of hypoglycemia when used alone, efficacy across a wide range of HbA1c levels, and the ability to lower glucose without stimulating insulin release or promoting weight gain. In fact, the caloric loss from urinary glucose excretion typically leads to a modest but sustained reduction in body weight — on the order of 2 to 4 kg over 6 to 12 months.
SGLT2 inhibitors lower the renal threshold for glucose excretion from approximately 180–200 mg/dL down to about 70–90 mg/dL. This means glucose begins to appear in the urine at much lower blood concentrations, creating a continuous "glycemic leak" that reduces hyperglycemia without relying on beta-cell function.
Beyond glycemic control, SGLT2 inhibitors produce osmotic diuresis and natriuresis, leading to reductions in intravascular volume, blood pressure (typically 3–6 mmHg systolic), and intraglomerular pressure. These hemodynamic effects — together with metabolic improvements — are thought to underlie the striking cardiovascular and renal benefits that have been demonstrated in large-scale outcome trials. The class also reduces uric acid levels, improves arterial stiffness, and decreases oxidative stress, adding to its cardioprotective profile.
"SGLT2 inhibitors represent a paradigm shift in diabetes care — from glucose-centric to organ-protective therapy. Their benefits extend well beyond HbA1c reduction."
— American Diabetes Association, Standards of Care in Diabetes, 2026
Cardiovascular and Renal Benefits: The Evidence Base
The landmark cardiovascular outcome trials (CVOTs) for SGLT2 inhibitors have fundamentally altered the treatment landscape for type 2 diabetes. The evidence for cardiorenal protection is now among the strongest of any glucose-lowering drug class.
Major Cardiovascular Outcome Trials
EMPA-REG OUTCOME (Empagliflozin, 2015): In 7,020 patients with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the primary composite endpoint (CV death, nonfatal MI, nonfatal stroke) by 14% (HR 0.86, p=0.04). The most striking finding was a 38% reduction in CV death and a 35% reduction in hospitalization for heart failure — effects that emerged within the first few months of treatment, suggesting hemodynamic rather than atherosclerotic mechanisms.
CANVAS Program (Canagliflozin, 2017): Pooled data from 10,142 participants showed a 14% reduction in the primary cardiovascular composite endpoint (HR 0.86) and a 33% reduction in heart failure hospitalization. Canagliflozin also showed a 27% reduction in the progression of albuminuria.
DECLARE-TIMI 58 (Dapagliflozin, 2019): In 17,160 patients — the largest CVOT for any SGLT2 inhibitor — dapagliflozin did not reduce MACE in the overall population but did reduce the composite of CV death or heart failure hospitalization by 17% (HR 0.83), driven largely by heart failure reduction. Dapagliflozin also showed renal benefit with a 24% reduction in the composite renal endpoint.
Renal Outcomes: The CREDENCE and DAPA-CKD Trials
CREDENCE (Canagliflozin, 2019) was the first dedicated renal outcomes trial for any SGLT2 inhibitor. In 4,401 patients with type 2 diabetes and albuminuric chronic kidney disease (eGFR 30–90 mL/min/1.73 m², UACR >300 mg/g), canagliflozin reduced the primary composite endpoint — ESKD, doubling of serum creatinine, or renal/cardiovascular death — by 30% (HR 0.70, p<0.001). The trial was stopped early due to overwhelming efficacy.
DAPA-CKD (Dapagliflozin, 2020) extended these findings to patients with and without type 2 diabetes. In 4,304 participants with CKD (eGFR 25–75, UACR 200–5000), dapagliflozin reduced the composite of worsening renal function, ESKD, or renal/cardiovascular death by 39% (HR 0.61). The benefit was consistent regardless of diabetes status.
The American Diabetes Association recommends SGLT2 inhibitors with proven cardiovascular benefit as first-line adjunctive therapy for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease — regardless of baseline HbA1c or metformin use (Grade A recommendation).
Approved SGLT2 Inhibitors: Comparison and Key Differences
Four SGLT2 inhibitors are currently approved in the United States and Europe for type 2 diabetes. While they share a common mechanism, important pharmacokinetic and clinical differences exist.
| Drug | Brand Name | Dose Range | Half-Life (h) | SGLT2/SGLT1 Selectivity | Key CVOT | eGFR Threshold |
|---|---|---|---|---|---|---|
| Empagliflozin | Jardiance | 10–25 mg daily | ~12.4 | ~2,500-fold | EMPA-REG OUTCOME | ≥20 mL/min |
| Dapagliflozin | Farxiga | 5–10 mg daily | ~12.9 | ~1,200-fold | DECLARE-TIMI 58, DAPA-HF, DAPA-CKD | ≥25 mL/min |
| Canagliflozin | Invokana | 100–300 mg daily | ~10.6 | ~250-fold | CANVAS, CREDENCE | ≥30 mL/min |
| Ertugliflozin | Steglatro | 5–15 mg daily | ~16.6 | ~2,000-fold | VERTIS CV | ≥30 mL/min |
All agents are administered once daily and require no dose titration for glycemic efficacy. Empagliflozin and dapagliflozin have the most favorable evidence in heart failure and CKD, and both carry FDA indications for heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status. Canagliflozin has the strongest dedicated renal outcome data (CREDENCE) and is also approved for diabetic kidney disease with albuminuria.
SGLT2 inhibitors become less effective for glucose lowering as eGFR declines, but cardiorenal benefits persist even at lower eGFR levels. In 2026, updated FDA labeling allows initiation or continuation of empagliflozin and dapagliflozin down to eGFR ≥20–25 mL/min/1.73 m² for cardiorenal indications. Canagliflozin and ertugliflozin carry a threshold of ≥30 mL/min.
Glycemic Efficacy and Place in Therapy
SGLT2 inhibitors lower HbA1c by an average of 0.5% to 1.0% depending on baseline HbA1c, renal function, and background therapy. The glucose-lowering effect is most pronounced in patients with higher baseline HbA1c and well-preserved renal function. Efficacy attenuates as eGFR declines below 45–60 mL/min/1.73 m², but the cardiorenal benefits remain dose-independent.
How do SGLT2 inhibitors compare with other glucose-lowering agents?
HbA1c reduction: 0.5–1.0%
Weight change: −2 to −4 kg
Hypoglycemia risk: Low (unless used with sulfonylureas or insulin)
Blood pressure: −3 to −6 mmHg systolic
Cardiorenal protection: Proven
Dosing: Once daily, oral
HbA1c reduction: 0.8–1.8%
Weight change: −3 to −6 kg
Hypoglycemia risk: Low
Blood pressure: −2 to −5 mmHg systolic
Cardiorenal protection: Proven (mainly atherosclerotic)
Dosing: Once daily to once weekly, injectable
Both SGLT2 inhibitors and GLP-1 receptor agonists are recommended as first-line adjunctive agents in patients with type 2 diabetes and established or high risk for ASCVD, HF, or CKD. The choice depends on individual patient factors: SGLT2 inhibitors are preferred when heart failure or CKD is the dominant concern, while GLP-1 agonists may be favored for patients with predominant atherosclerotic disease or those who require greater weight loss and glycemic reduction.
Safety Profile, Side Effects, and Contraindications
SGLT2 inhibitors are generally well tolerated, but they are associated with a distinct set of adverse effects that clinicians and patients must recognize. The most common side effects are related to the mechanism of action — glucosuria — and include genital mycotic infections and urinary tract infections.
Genital mycotic infections: Vulvovaginal candidiasis and balanitis occur in 5–10% of patients, more frequently in women and uncircumcised men. Risk can be reduced with proper hygiene but not eliminated. These are typically mild and treatable with topical antifungals.
Urinary tract infections: Slightly increased risk, though most trials showed no significant difference vs placebo. Patients with recurrent UTIs should be monitored closely.
Volume depletion: Due to osmotic diuresis, especially in older adults, patients on loop diuretics, or those with reduced intravascular volume. Advise adequate hydration and consider dose adjustment of concomitant diuretics.
Serious Adverse Effects and Warnings
SGLT2 inhibitors are contraindicated in patients with a history of serious hypersensitivity reaction to any agent in the class, and should generally be avoided during pregnancy (no safety data), in patients with severe hepatic impairment, and in those with a history of diabetic ketoacidosis without clear precipitating factors.
Patient Selection and Practical Prescribing
Not every patient with type 2 diabetes is a candidate for SGLT2 inhibitor therapy. The decision to prescribe should be individualized based on clinical phenotype, comorbid conditions, and patient preferences. The strongest indications for SGLT2 inhibitor use include:
- Established ASCVD (prior MI, stroke, or revascularization) — empagliflozin or canagliflozin preferred
- Heart failure with reduced ejection fraction (HFrEF) — empagliflozin or dapagliflozin, regardless of diabetes status
- Chronic kidney disease with albuminuria — dapagliflozin or canagliflozin, with eGFR thresholds noted above
- Need for weight loss or avoidance of weight gain — SGLT2 inhibitors promote modest but sustained weight reduction
- Poor glycemic control with previous therapy — especially when combined with metformin, GLP-1 agonists, or insulin
How to initiate and monitor SGLT2 inhibitor therapy
SGLT2 inhibitors pair well with metformin (additive HbA1c reduction without increased hypoglycemia), GLP-1 receptor agonists (complementary weight loss and cardiorenal protection), and basal insulin (reduced insulin dose requirement). The combination of SGLT2 inhibitor + GLP-1 agonist is increasingly recognized as a powerful dual-therapy approach for high-risk patients.
Common Myths and Misconceptions About SGLT2 Inhibitors
The opposite is true. SGLT2 inhibitors reduce intraglomerular pressure by restoring tubuloglomerular feedback, leading to an initial small drop in eGFR (the "hemodynamic dip") that is temporary and not indicative of injury. Long-term, they slow the progression of kidney disease — as demonstrated in CREDENCE and DAPA-CKD.
Empagliflozin and dapagliflozin are now FDA-approved for heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status. Dapagliflozin is also approved for chronic kidney disease with albuminuria in patients with and without type 2 diabetes. The cardiorenal benefits are independent of glycemic effects.
The risk of UTI is modestly increased in some studies, but most meta-analyses show no statistically significant increase compared with placebo. Genital mycotic infections are far more common. Good genital hygiene reduces risk, and these infections are easily treatable. For most patients, the cardiorenal benefits far outweigh the infectious risk.
This is outdated. Current labeling allows use down to eGFR ≥20–25 mL/min/1.73 m² for empagliflozin and dapagliflozin. While glucose-lowering efficacy diminishes at lower eGFR, the renal protective effects remain robust. In fact, CKD with albuminuria is one of the strongest indications for SGLT2 inhibitor therapy.
Frequently Asked Questions About SGLT2 Inhibitors
What does SGLT2 stand for?
SGLT2 stands for sodium-glucose cotransporter-2, a protein expressed primarily in the proximal convoluted tubule of the kidney. It is responsible for reabsorbing approximately 90% of the glucose that is filtered through the glomerulus. Inhibiting this transporter causes glucose to be excreted in the urine, lowering blood glucose levels.
How long does it take for SGLT2 inhibitors to work?
The glucose-lowering effect begins within the first 24 hours of the first dose, as SGLT2 inhibition immediately induces glucosuria. HbA1c reductions are typically seen within 4–8 weeks, with full effect by 12–16 weeks. The cardiovascular and renal benefits — such as reductions in heart failure hospitalizations — can appear within the first few months of therapy.
Can SGLT2 inhibitors be used with insulin?
Yes, SGLT2 inhibitors are commonly used in combination with insulin. This combination often allows for a reduction in total daily insulin dose by 10–20% while improving glycemic control and promoting weight loss. However, caution is needed to avoid hypoglycemia; insulin doses should be adjusted downward at initiation, especially in patients with HbA1c near target.
What is euglycemic DKA, and how can it be prevented?
Euglycemic DKA is a rare but serious complication of SGLT2 inhibitor therapy in which ketoacidosis occurs without marked hyperglycemia (blood glucose typically <250 mg/dL). It can be triggered by insulin dose reduction, acute illness, surgery, prolonged fasting, very low-carbohydrate diets, or excessive alcohol intake. Prevention includes careful patient education, holding the medication during periods of acute illness or prior to surgery, and ensuring adequate insulin in type 1 diabetes (SGLT2 inhibitors are not approved for type 1 diabetes in most regions).
Are SGLT2 inhibitors safe in older adults?
Yes, with appropriate precautions. Older adults are more susceptible to volume depletion, orthostatic hypotension, and falls. SGLT2 inhibitors should be initiated at the lowest dose, with careful assessment of hydration status, concurrent diuretic use, and renal function. The cardiorenal benefits of SGLT2 inhibitors are particularly valuable in older patients with high cardiovascular and renal risk. Consider reducing concomitant diuretic doses if volume depletion occurs.
Can SGLT2 inhibitors cause weight loss?
Yes, SGLT2 inhibitors typically produce modest but sustained weight loss of 2–4 kg (approximately 4–9 pounds) over 6–12 months. The mechanism is caloric loss through urinary glucose excretion — approximately 200–300 calories lost per day, depending on the degree of hyperglycemia. Weight loss tends to plateau after several months and is less pronounced than with GLP-1 receptor agonists, but it is clinically meaningful and contributes to overall metabolic improvement.
